内分泌学とメタボリックシンドローム

内分泌学とメタボリックシンドローム
オープンアクセス

ISSN: 2161-1017

概要

Circulating Omentin-1 in Obesity and Metabolic Syndrome Status Compared to Control Subjects

Arash Hossein-nezhad, Khadijeh Mirzaei, Soudabeh Alatab, Zahra Ahmadivand and Azam Najmafshar

Background and aim: The goal of this study was to investigate the association between omentin-1 and different biochemical and anthropometric parameters in obese and non-obese, also in patients with metabolic syndrome compared to the healthy control group.

Methods: A total of 81 women were included in the current case-control study. Based on their BMI they were divided into obese and non-obese groups and according to WHO criteria for metabolic syndrome they were divided in to metabolic syndrome group and healthy subjects. Fasting blood sample was collected to determine biochemical indicators and insulin resistance and sensitivity indices (HOMA-IR and Quicki). Omentin-1 plasma level was assessed by ELISA. Association of omentin-1 with biochemical markers was studied. Body composition was measured using Body composition analyzer BC-418MA- Tanita.

Results: Levels of omentin-1 were lower in obese than non-obese subjects. It was also lower in patients with metabolic syndrome than in healthy ones. In correlation analysis, omentin-1 was associated with waist circumference, fat percent and fat mass and nearly visceral fat. But there was no significant relation between omentin and any insulin resistance indices.

Conclusions: In conclusion, omentin-1 is an adipokine closely associated with visceral obesity, but not with insulin resistance, and glucose metabolism; its serum concentration is decreased in the state of obesity and the regulation of omentin-1 production in adipose tissue is probably multifactorial. Future analysis of omentin’s biological actions, and measurement of omentin-1 levels in the omental depot as well as in the circulation of humans with or without obesity and its co morbidities, will help to define its role in the pathogenesis of these diseases.

免責事項: この要約は人工知能ツールを使用して翻訳されたものであり、まだレビューまたは検証されていません。
Top